A pilot study to evaluate the efficacy of Phalatrikadi Ghana Vati in patients of Non - alcoholic fatty liver disease
Phase 2
- Conditions
- Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
- Registration Number
- CTRI/2022/06/043428
- Lead Sponsor
- Dr Piyush Chaudhary
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Ultrasonography (USG) abdomen suggestive of NAFLD with or without symptoms like pain in right upper quadrant/epigastric region of the abdomen, feeling of nausea, and vomiting, loss of appetite, burning sensation in the abdomen.
2.Liver function tests showing raised alanine transaminases (ALT) or aspartate transaminases (AST) levels raised above the normal limits (40IU/L) up to 300 IU/L
Exclusion Criteria
1. Patients unwilling to participate in study
2. Patients with a history of alcohol intake exceeding 20 g/day (Alcohol consumption history shall be separately obtained from the patients and family)
3. Patients testing positive for markers of other viral hepatitis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in symptoms Udarasula (pain in abdomen), utklesa (feeling of nausea and vomiting), agnimandya (impaired digestion), klama (Fatigue), aruci (loss of appetite), sadana (malaise) <br/ ><br> <br/ ><br>& Improvement in USG for NAFLD Improvement in BMI, ALT, AST & ALT/AST Ratio & Lipid ProfileTimepoint: baseline And 84 days
- Secondary Outcome Measures
Name Time Method 1. mprovement in symptoms Udarasula (pain in abdomen), utklesa (feeling of nausea and vomiting), agnimandya (impaired digestion), klama (Fatigue), aruci (loss of appetite), sadana (malaise)Timepoint: Baseline, 28th day, 56th day and 84 days